mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants-Reference-Cited by-同舟云学术

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

Published:2021-02-10 Issue:7855 Volume:592 Page:616-622
ISSN:0028-0836
Container-title:Nature
language:en
Short-container-title:Nature

Author:

Wang Zijun,Schmidt Fabian,Weisblum Yiska,Muecksch Frauke^ORCID,Barnes Christopher O.,Finkin Shlomo^ORCID,Schaefer-Babajew Dennis^ORCID,Cipolla Melissa,Gaebler Christian^ORCID,Lieberman Jenna A.,Oliveira Thiago Y.^ORCID,Yang Zhi,Abernathy Morgan E.,Huey-Tubman Kathryn E.,Hurley Arlene,Turroja Martina^ORCID,West Kamille A.,Gordon Kristie,Millard Katrina G.^ORCID,Ramos Victor^ORCID,Da Silva Justin^ORCID,Xu Jianliang^ORCID,Colbert Robert A.,Patel Roshni,Dizon Juan,Unson-O’Brien Cecille,Shimeliovich Irina,Gazumyan Anna,Caskey Marina^ORCID,Bjorkman Pamela J.^ORCID,Casellas Rafael^ORCID,Hatziioannou Theodora^ORCID,Bieniasz Paul D.^ORCID,Nussenzweig Michel C.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/s41586-021-03324-6.pdf

Reference66 articles.

1. Gaebler, C. & Nussenzweig, M. C. All eyes on a hurdle race for a SARS-CoV-2 vaccine. Nature 586, 501–502 (2020).

2. Jackson, L. A. et al. An mRNA vaccine against SARS-CoV-2 – preliminary report. N. Engl. J. Med. 383, 1920–1931 (2020).

3. Krammer, F. SARS-CoV-2 vaccines in development. Nature 586, 516–527 (2020).

4. Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603–2615 (2020).

5. Gaebler, C. et al. Evolution of antibody immunity to SARS-CoV-2. Nature, https://doi.org/10.1038/s41586-021-03207-w (2021).

Cited by 1056 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chemically Modified Platforms for Better RNA Therapeutics;Chemical Reviews;2024-01-29

2. Mutational signature dynamics indicate SARS-CoV-2’s evolutionary capacity is driven by host antiviral molecules;PLOS Computational Biology;2024-01-25

3. Hybrid immunity to SARS-CoV-2 arises from serological recall of IgG antibodies distinctly imprinted by infection or vaccination;2024-01-23

4. What makes SARS‐CoV‐2 unique? Focusing on the spike protein;Cell Biology International;2024-01-23

5. Machine learning-based approach KEVOLVE efficiently identifies SARS-CoV-2 variant-specific genomic signatures;PLOS ONE;2024-01-19